- Home
- UNCY vs LUNG Comparison
UNCY vs LUNG Comparison
Compare UNCY & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- LUNG
- Stock Information
- Founded
- UNCY 2016
- LUNG 1995
- Country
- UNCY United States
- LUNG United States
- Employees
- UNCY N/A
- LUNG N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- LUNG Industrial Specialties
- Sector
- UNCY Health Care
- LUNG Health Care
- Exchange
- UNCY Nasdaq
- LUNG Nasdaq
- Market Cap
- UNCY 74.2M
- LUNG 65.6M
- IPO Year
- UNCY 2021
- LUNG 2020
- Fundamental
- Price
- UNCY $4.63
- LUNG $1.72
- Analyst Decision
- UNCY Strong Buy
- LUNG Buy
- Analyst Count
- UNCY 5
- LUNG 7
- Target Price
- UNCY $55.20
- LUNG $7.66
- AVG Volume (30 Days)
- UNCY 510.5K
- LUNG 317.4K
- Earning Date
- UNCY 11-12-2025
- LUNG 10-29-2025
- Dividend Yield
- UNCY N/A
- LUNG N/A
- EPS Growth
- UNCY N/A
- LUNG N/A
- EPS
- UNCY N/A
- LUNG N/A
- Revenue
- UNCY N/A
- LUNG $90,549,000.00
- Revenue This Year
- UNCY N/A
- LUNG $10.30
- Revenue Next Year
- UNCY $4,481.14
- LUNG $14.72
- P/E Ratio
- UNCY N/A
- LUNG N/A
- Revenue Growth
- UNCY N/A
- LUNG 18.24
- 52 Week Low
- UNCY $3.40
- LUNG $1.47
- 52 Week High
- UNCY $11.00
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- UNCY 61.71
- LUNG 47.63
- Support Level
- UNCY $3.72
- LUNG $1.69
- Resistance Level
- UNCY $4.80
- LUNG $1.94
- Average True Range (ATR)
- UNCY 0.24
- LUNG 0.11
- MACD
- UNCY 0.07
- LUNG 0.02
- Stochastic Oscillator
- UNCY 75.00
- LUNG 41.65
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.